Phase II Trial of the Impact 0.5% Povidone‐Iodine Nasal Spray (Nasodine®) on Shedding of SARS‐CoV‐2
MD Peter L Friedland, PhD Simon Tucker
The Laryngoscope, doi:10.1002/lary.31430
Objective: A Phase II trial was conducted to determine if nasal disinfection with a commercial Good Manufacturing Practice-manufactured 0.5% povidone-iodine nasal spray (Nasodine ® ) may be a useful adjunct in the management of COVID-19 by reducing viral shedding and prevention of transmission of SARS-CoV-2. The aim was to confirm the results from a human single-dose pilot study by assessing repeated and frequent doses on nasal shedding of SARS-CoV-2 from adult subjects with confirmed COVID-19. Methods: A multicenter, randomized, double-blinded, placebo-controlled Phase II clinical trial involving adults with early COVID-19 symptoms. Baseline nasal swabs were collected to quantify pretreatment SARS-CoV-2 nasal viral load, followed by Nasodine treatment eight times daily over 3 calendar days. Daily nasal swabs were collected post-dose to assess the impact of treatment on nasal viral load, measured by log10 TCID50 in quantitative culture. Results: Nasodine subjects exhibited significantly improved reduction in viral load (log10 TCID50) on Days 2-4 compared to placebo recipients (p = 0.028), rate of nasal clearance of viable virus (p = 0.032), and complete (100%) nasal and throat clearance of the virus by Day 5. No difference was seen in antigen shedding as measured by time transition from Rapid Antigen Test (RAT) positivity to RAT negativity. Conclusion: A total of 20 doses of Nasodine ® nasal spray administered over 2.5 days significantly reduced the titers of viable SARS-CoV-2 virus in the nasal passages of COVID-19 subjects. This is the first study demonstrating the efficacy of a tolerable intranasal formulation of povidone-iodine on viral shedding in COVID-19 subjects. Nasal disinfection may diminish viral transmission to others.
References
Anderson, Sivalingam, Kang, Povidone-iodine demonstrates rapid in vitro Virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease, Infect Dis Ther,
doi:10.1007/s40121-020-00316-3Arefin, Rumi, Uddin, Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial, Indian J Otolaryngol Head Neck Surg,
doi:10.1007/s12070-021-02616-7Baxter, Schwartz, Johnson, Rapid initiation of nasal saline irrigation to reduce severity in high-risk COVID+ outpatients: a randomized clinical trial compared to a national dataset observational arm,
doi:10.1101/2021.08.16.21262044Bidra, Pelletier, Westover, Frank, Brown et al., Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine Oral antiseptic rinse, J Prosthodont,
doi:10.1111/jopr.13209Campbell, SARS-CoV-2 and the nose: risks and implications for primary care, Aust J Gen Pract
Choudhury, Effect of 1% povidone iodine mouthwash/gargle, nasal and eye drop in COVID-19 patient, Biores Commun
Elsersy, Zahran, Elbakry, Combined nasal, oropharyngeal povidone iodine plus Glycyrrhizic acid sprays, accelerate clinical and laboratory recovery and reduces household transmission of SARS-CoV-2: a randomized placebo-controlled clinical trial, Front Med,
doi:10.3389/fmed.2022.863917Frank, Brown, Capriotti, Westover, Pelletier et al., In vitro efficacy of a povidone-iodine nasal antiseptic for rapid inactivation of SARS-CoV-2, JAMA Otolaryngol Head Neck Surg,
doi:10.1001/jamaoto.2020.3053Friedland, Tucker, Goodall, In vivo (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray, Aust J Otolaryngol,
doi:10.21037/ajo-21-40Gallo, Locatello, Mazzoni, Novelli, Annunziato, The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection, Mucosal Immunol,
doi:10.1038/s41385-020-00359-2Guenezan, Garcia, Strasters, Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19: a randomized clinical trial, JAMA Otolaryngol Head Neck Surg,
doi:10.1001/jamaoto.2020.5490Hale, Lux, Kim, In vitro Nasodine can be an effective Antibiofilm agent for biofilms that may cause CRS, Laryngoscope,
doi:10.1002/lary.30558Jamir, Tripathi, Shankar, Kakkar, Ayyanar et al., Determinants of outcome among critically ill police personnel with COVID-19: a retrospective observational study from Andhra Pradesh, India, Cureus,
doi:10.7759/cureus.20394Kawana, Kitamura, Nakagomi, Inactivation of human viruses by povidone-iodine in comparison with other antiseptics, Dermatology,
doi:10.1159/000246027Lachapelle, Casado, Antiseptics in the era of bacterial resistance: a focus on povidone iodine, Future Med
Lepelletier, Maillard, Pozzetto, Simon, Povidone iodine: properties, mechanisms of action, and role in infection control and Staphylococcus aureus decolonization, Antimicrob Agents Chemother,
doi:10.1128/AAC.00682-20Ma, Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
Mady, Kubik, Baddour, Snyderman, Rowan, Consideration of povidone-iodine as a public health intervention for COVID-19: utilization as "personal protective equipment" for frontline providers exposed in high-risk head and neck and skull base oncology care, Oral Oncol,
doi:10.1016/j.oraloncology.2020.104724Naqvi, Citardi, Cattano, Ostrosky-Zeichner, Knackstedt et al., Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework, J Otolaryngol Head Neck Surg,
doi:10.1186/s40463-020-00474-xNuckolls, Chemical considerations related to the dilution of commercial 10% Povidone-iodine for use in the COVID-19 Pandemic
Ramezanpour, Smith, Psaltis, Wormald, Vreugde, In vitro safety evaluation of a povidone-iodine solution applied to human nasal epithelial cells, Int Forum Allergy Rhinol,
doi:10.1002/alr.22575Sirijatuphat, Leelarasamee, Puangpet, Thitithanyanont, A pilot study of 0.4% povidone-iodine nasal spray to eradicate SARS-CoV-2 in the nasopharynx, Infect Drug Resist,
doi:10.2147/IDR.S391630Zarabanda, Vukkadala, Phillips, The effect of povidone-iodine nasal spray on nasopharyngeal SARS-CoV-2 viral load: a randomized control trial, Laryngoscope,
doi:10.1002/lary.29935{ 'indexed': {'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T12:13:07Z', 'timestamp': 1711800787343},
'reference-count': 25,
'publisher': 'Wiley',
'license': [ { 'start': { 'date-parts': [[2024, 3, 30]],
'date-time': '2024-03-30T00:00:00Z',
'timestamp': 1711756800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True},
'abstract': '<jats:sec><jats:title>Objective</jats:title><jats:p>A Phase II trial was conducted to '
'determine if nasal disinfection with a commercial Good Manufacturing Practice‐manufactured '
'0.5% povidone‐iodine nasal spray (Nasodine®) may be a useful adjunct in the management of '
'COVID‐19 by reducing viral shedding and prevention of transmission of SARS‐CoV‐2. The aim was '
'to confirm the results from a human single‐dose pilot study by assessing repeated and '
'frequent doses on nasal shedding of SARS‐CoV‐2 from adult subjects with confirmed '
'COVID‐19.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A multicenter, '
'randomized, double‐blinded, placebo‐controlled Phase II clinical trial involving adults with '
'early COVID‐19 symptoms. Baseline nasal swabs were collected to quantify pretreatment '
'SARS‐CoV‐2 nasal viral load, followed by Nasodine treatment eight times daily over 3 calendar '
'days. Daily nasal swabs were collected post‐dose to assess the impact of treatment on nasal '
'viral load, measured by log10 TCID50 in quantitative '
'culture.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Nasodine '
'subjects exhibited significantly improved reduction in viral load (log10 TCID50) on Days 2–4 '
'compared to placebo recipients (<jats:italic>p</jats:italic>\u2009=\u20090.028), rate of '
'nasal clearance of viable virus (<jats:italic>p</jats:italic>\u2009=\u20090.032), and '
'complete (100%) nasal and throat clearance of the virus by Day 5. No difference was seen in '
'antigen shedding as measured by time transition from Rapid Antigen Test (RAT) positivity to '
'RAT negativity.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>A '
'total of 20 doses of Nasodine® nasal spray administered over 2.5\u2009days significantly '
'reduced the titers of viable SARS‐CoV‐2 virus in the nasal passages of COVID‐19 subjects. '
'This is the first study demonstrating the efficacy of a tolerable intranasal formulation of '
'povidone‐iodine on viral shedding in COVID‐19 subjects. Nasal disinfection may diminish viral '
'transmission to others.</jats:p></jats:sec><jats:sec><jats:title>Level of '
'Evidence</jats:title><jats:p>Level 2 <jats:italic>Laryngoscope</jats:italic>, '
'2024</jats:p></jats:sec>',
'DOI': '10.1002/lary.31430',
'type': 'journal-article',
'created': {'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T11:29:42Z', 'timestamp': 1711798182000},
'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Phase <scp>II</scp> Trial of the Impact 0.5% Povidone‐Iodine Nasal Spray (Nasodine®) on Shedding '
'of <scp>SARS‐CoV</scp>‐2',
'prefix': '10.1002',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2686-8516',
'authenticated-orcid': False,
'given': 'Peter L.',
'family': 'Friedland',
'sequence': 'first',
'affiliation': [ { 'name': 'Faculty of Medical and Health Sciences University of Western '
'Australia Crawley Western Australia Australia'},
{ 'name': 'Department Otorhinolaryngology Head Neck Skull Base Surgery Sir '
'Charles Gairdner Hospital Nedlands Western Australia Australia'},
{'name': 'Firebrick Pharma Limited Melbourne Victoria Australia'}]},
{ 'given': 'Simon',
'family': 'Tucker',
'sequence': 'additional',
'affiliation': [{'name': 'Firebrick Pharma Limited Melbourne Victoria Australia'}]}],
'member': '311',
'published-online': {'date-parts': [[2024, 3, 30]]},
'reference': [ {'key': 'e_1_2_7_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.31128/AJGP-05-20-5452'},
{ 'key': 'e_1_2_7_3_1',
'doi-asserted-by': 'crossref',
'unstructured': 'HouYJ OkudaK EdwardsCE et al.SARS‐CoV‐2 reverse genetics reveals a '
'variable infection gradient in the respiratory tract. (1097–4172 '
'(Electronic)) (In eng). '
'2020;182(2):429‐446.https://doi.org/10.1016/j.cell.2020.05.042',
'DOI': '10.1016/j.cell.2020.05.042'},
{'key': 'e_1_2_7_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41385-020-00359-2'},
{'key': 'e_1_2_7_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.00682-20'},
{ 'key': 'e_1_2_7_6_1',
'first-page': '579',
'article-title': 'Antiseptics in the era of bacterial resistance: a focus on povidone '
'iodine',
'volume': '10',
'author': 'Lachapelle JMCO',
'year': '2013',
'journal-title': 'Future Med'},
{'key': 'e_1_2_7_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1159/000246027'},
{'key': 'e_1_2_7_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40121-020-00316-3'},
{'key': 'e_1_2_7_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s40463-020-00474-x'},
{'key': 'e_1_2_7_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41415-020-1589-4'},
{ 'key': 'e_1_2_7_11_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.oraloncology.2020.104724'},
{'key': 'e_1_2_7_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamaoto.2020.3053'},
{'key': 'e_1_2_7_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jopr.13209'},
{ 'key': 'e_1_2_7_14_1',
'unstructured': 'MaG.Prevention of infection by highly pathogenic viruses using topical '
'application of povidone‐iodine on mucous membranes.2020.'},
{'key': 'e_1_2_7_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamaoto.2020.5490'},
{'key': 'e_1_2_7_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/lary.29935'},
{'key': 'e_1_2_7_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2147/IDR.S391630'},
{'key': 'e_1_2_7_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3329/brc.v7i1.54245'},
{'key': 'e_1_2_7_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12070-021-02616-7'},
{ 'key': 'e_1_2_7_20_1',
'doi-asserted-by': 'crossref',
'unstructured': 'BaxterAL SchwartzKR JohnsonRW et al.Rapid initiation of nasal saline '
'irrigation to reduce severity in high‐risk COVID+ outpatients: a '
'randomized clinical trial compared to a national dataset observational '
'arm.2021https://doi.org/10.1101/2021.08.16.21262044',
'DOI': '10.1101/2021.08.16.21262044'},
{'key': 'e_1_2_7_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.20394'},
{'key': 'e_1_2_7_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fmed.2022.863917'},
{ 'key': 'e_1_2_7_23_1',
'doi-asserted-by': 'crossref',
'unstructured': 'NuckollsC.Chemical considerations related to the dilution of commercial '
'10% Povidone‐iodine for use in the COVID‐19 Pandemic.2020.',
'DOI': '10.31219/osf.io/8kepw'},
{'key': 'e_1_2_7_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/alr.22575'},
{'key': 'e_1_2_7_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.21037/ajo-21-40'},
{'key': 'e_1_2_7_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/lary.30558'}],
'container-title': 'The Laryngoscope',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/lary.31430',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 3, 30]],
'date-time': '2024-03-30T11:29:47Z',
'timestamp': 1711798187000},
'score': 1,
'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/lary.31430'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 3, 30]]},
'references-count': 25,
'alternative-id': ['10.1002/lary.31430'],
'URL': 'http://dx.doi.org/10.1002/lary.31430',
'relation': {},
'ISSN': ['0023-852X', '1531-4995'],
'subject': ['Otorhinolaryngology'],
'container-title-short': 'The Laryngoscope',
'published': {'date-parts': [[2024, 3, 30]]},
'assertion': [ { 'value': '2023-11-29',
'order': 0,
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-03-12',
'order': 1,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-03-30',
'order': 2,
'name': 'published',
'label': 'Published',
'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
